The drug, co-developed by Regeneron Pharmaceuticals and Sanofi, first earned FDA approval in July 2015. The new once-monthly dose of the drug allows clinicians to offer a more personalized cholesterol treatment plan for patients, according to a news release.
Praluent sits at the center of a patent dispute filed October 2014 against Regeneron and Sanofi by Amgen, which makes the rival cholesterol drug Repatha. While a district judge blocked sales of Praluent Jan. 5 after Amgen won the patent lawsuit, the U.S. Court of Appeals in February ruled the drugmakers could continue to sell the medication as they undergo the appeals process.
More articles on supply chain:
3 things to know about National Prescription Drug Take Back Day
Pharmacist lobby group: PBMs prioritize profits over medication affordability
FDA targets 14 companies advertising fake cancer products
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
